Britain and America have finalized a key commercial pact that will preserve zero duties on UK medicine shipments going into the American market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has pledged to increase funding on medicines through the NHS. This move secures that duties on these key products will stay at zero for a period of three years.
This deal is in response to previous threats to significantly raise duties on branded drug imports, with potential rates floated as high as double the cost.
"This arrangement with the United Kingdom reinforces the international landscape for cutting-edge drugs and establishes much-needed balance to transatlantic drug exports," an announcement said.
Trade Importance
Drugs represent one of the UK's most significant export categories to the US, which is by far the primary market for large British pharmaceutical firms.
Trade data reveal that in the one-year period leading up to the third quarter, the UK exported medicines valued at £11.1bn to the US. This figure accounted for a significant portion of British export trade in that period.
"This deal secures jobs, stimulates funding and paves the way for the UK to become a worldwide center for life sciences," the Business and Trade Secretary commented.
Key NHS Changes
The deal entails several specific changes from the British government:
- Revised Affordability Limit: The UK will raise the affordability limit at which it judges new medicines to be too expensive by 25%.
- Higher Drug Budget: There is a target to double total health service expenditure on treatments from 0.3 percent of GDP to 0.6% over the following ten-year period.
- Rebate Cap: The sum pharmaceutical firms must refund to the NHS to stay within budget will be limited at fifteen percent. Previously, rebates were more than 20%.
Recent Tensions
The deal takes place against a long-running row between the sector and the UK government over medicine costs and regulatory access.
This friction were exacerbated by assertions that US patients were paying several times more for the same drugs than people in the Britain and the EU.
Over the last 18 months, several significant pharmaceutical investments in the UK have been halted or cancelled, while major funding commitments have been directed toward projects in the United States.
One official stated that the NHS had to increase expenditure on treatments, noting that its budget allocation on drugs had declined as a share of its total funding over the previous ten-year period.
